Regeneron PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Regeneron PharmaceuticalsAntibody biotech behind Eylea and Dupixent. Its GLP-1 exposure is complementary rather than competitive: the Phase 2 COURAGE trial adds trevogrumab (anti-myostatin), with or without garetosmab, on top of semaglutide to protect lean mass. At 26 weeks the combination prevented roughly half the lean-mass loss seen with semaglutide alone.
2021-Q3-2026-Q2
2021-Q3-2026-Q2
1996-2025
$REGN
Not a GLP-1 competitor but a combination play. Phase 2 COURAGE adds trevogrumab (anti-myostatin), with or without garetosmab, on top of semaglutide to protect lean mass. At 26 weeks the doublet prevented roughly half the lean-mass loss seen with semaglutide alone; the triplet preserved over 80% of lean mass and cut fat 27.3% more than semaglutide, but discontinuations reached 30.9%. Trial completes late 2026.